COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ..
A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxis was added. With these treatments, the patient has made a good recovery, and he was discharged on hospital day 11. There is no standard strategy for prophylaxis of thrombosis in patients with ET, and apixaban could be a clinical benefit for these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
BMJ case reports - 14(2021), 11 vom: 30. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Takasaki, Kazuki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3Z9Y7UWC1J |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 14.12.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bcr-2021-246700 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333854101 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333854101 | ||
| 003 | DE-627 | ||
| 005 | 20231225222511.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bcr-2021-246700 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333854101 | ||
| 035 | |a (NLM)34848425 | ||
| 035 | |a (PII)e246700 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Takasaki, Kazuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxis was added. With these treatments, the patient has made a good recovery, and he was discharged on hospital day 11. There is no standard strategy for prophylaxis of thrombosis in patients with ET, and apixaban could be a clinical benefit for these patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a medical management | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a apixaban |2 NLM | |
| 650 | 7 | |a 3Z9Y7UWC1J |2 NLM | |
| 700 | 1 | |a Tsunenari, Takazumi |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Kazuma |e verfasserin |4 aut | |
| 700 | 1 | |a Aochi, Satsuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ case reports |d 2008 |g 14(2021), 11 vom: 30. Nov. |w (DE-627)NLM209291001 |x 1757-790X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:11 |g day:30 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bcr-2021-246700 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 11 |b 30 |c 11 | ||